Insmed (INSM) Receives a Buy from TD Cowen
In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Insmed (INSM – Research Report), with a price target of $98.00.
Insmed Stock Surges on Trial Win for Lung-Condition Drug. ‘We Hit the Mark,’ CEO Says.
In a note early Tuesday, TD Cowen analyst Ritu Baral said that the outcome of the brensocatib trial at both dosage levels was ...
Business Insider25d
TD Cowen Remains a Buy on Vera Therapeutics (VERA)
TD Cowen analyst Ritu Baral reiterated a Buy rating on Vera Therapeutics (VERA – Research Report) yesterday and set a price target of $60.00. The company’s shares closed last Friday at $27.46.
Investing9d
Krystal Biotech at TD Cowen Conference: Strategic Pipeline Progress
Distributor relationships are being explored in the Middle East and North Africa. Ritu Baral, Analyst, TD Cowen: We’re going to go ahead and get started. Thank you very much for joining us for ...